DSS, Inc. Announces Form F-4 Filing in Connection with Impact Biomedical’s Proposed Business Combination with Zoar Limited
Impact Biomedical Inc IBO
$5.69
▲ +0.71%
(+$0.04)
🎢 High Beta
Open
$5.80
Prev Close
$5.65
Day Range
$5.58 – $6.50
52W Range
$4.67 – $10.47
Market Cap
$48.61M
P/E (TTM)
61.18
Beta
-1.36
EPS (TTM)
$-0.09
📋 Company Profile
| Industry | Pharmaceuticals |
| Country | US |
| Exchange | NYSE MKT LLC |
| Currency | USD |
| IPO Date | 2024-09-16 |
| Shares Out. | 107,820,000 |
| Website | impactbiomedinc.com/ ↗ |
| Phone | 15852321500 |
| Employees | 8 |
| Revenue | $3,000 |
| Gross Profit | -$16,000 |
| Net Income | -$700,000 |
| Free Cash Flow | -$508,000 |
| Total Assets | $16.7M |
| Total Liabilities | $2.7M |
| Equity | $14.0M |
About Impact Biomedical Inc
Impact BioMedical Inc focuses on the advancement of drug discovery and prevention, inhibition, and treatment of neurological, oncological, and immune-related diseases. The company is also developing open-air defense initiatives, which curb transmission of air-borne infectious diseases, such as tuberculosis and influenza. Its technologies inlcude Linebacker, Laetose, 3F, and Equivir.
Impact Biomedical Inc is a publicly traded company under the ticker symbol IBO on the NYSE MKT LLC, operating in the Pharmaceuticals industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📰 Latest News for IBO
Impact Biomedical Inc Announces Filing of Form F-4 Registration Statement in Connection with Proposed Merger with Zoar Ltd. (f/k/a Dr. Ashley’s Limited)
CORRECTED — Impact Biomedical Inc (NYSE: IBO) Announces 1 for 12.62 Reverse Stock Split to Pursue Completion of Merger with Zoar Limited (f/k/a Dr Ashleys Limited)